Professor of Medicine, Case West Res University
Hematology
Dr. Pierre L. Triozzi, MD
|
|
Give Review
Doctor Pierre L. Triozzi, MD works in the field of Hematology. He studied medicine at The Ohio State University College of Medicine. He over the years received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Pierre Triozzi is also published. He has 98 publications published. The lastest publication: "Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer.' He accepts Medicare.
Publications
- Depression, Anxiety, and Regret Before and After Testing to Estimate Uveal Melanoma Prognosis.
- Fine-needle aspiration biopsy of uveal Melanoma: outcomes and complications.
- Dual VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and pharmacodynamic biomarkers.
- Circulating immune Cell and microRNA in patients with uveal melanoma developing metastatic disease.
- Phase 1 Dose-Escalation Study of VB-111, an Anti-Angiogenic Virotherapy, in Patients with Advanced Solid Tumors.
- Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal Melanoma.
- Monosomy 3 by FISH in uveal Melanoma: variability in techniques and results.
- VB-111 for Cancer.
- Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal Melanoma.
- Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent Cellular cytotoxicity.
- A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic Melanoma.
- Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate Cancer.
- Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected Melanoma at risk for relapse.
- Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic Melanoma.
- High efficiency transduction of dendritic Cells by adenoviral vectors targeted to DC-SIGN.
- Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor ...
- Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic Melanoma.
- Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.
- Enhanced gene transfer to mouse dendritic Cells using adenoviral vectors coated with a novel adapter molecule.
- Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.
- Genetically targeted adenovirus vector directed to CD40-expressing Cells.
- Infusion of unpulsed dendritic Cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ Cells and monocytes in patients wit...
- Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal Cancer: antibody response is associated w...
- Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal Melanoma prognostication.
- The role of the immune response in merkel Cell carcinoma.
- Circulating melanoma Cells: scoping the target.
- Blood biomarkers for uveal Melanoma.
- Re-inventing intratumoral immunotherapy for Melanoma.
- Blood biomarkers of uveal Melanoma metastasis.
- Regulation of the activity of an adeno-associated virus vector Cancer vaccine administered with synthetic Toll-like receptor agonists.
- Differential effects of imatinib mesylate against uveal Melanoma in vitro and in vivo.
- Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established Melanoma.
- Immunization of colorectal Cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and wit...
- A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).
- Targeted therapy for uveal Melanoma.
- Phase II study of pyrazoloacridine in metastatic renal Cell carcinoma.
- Intratumoral injection of dendritic cells derived in vitro in patients with metastatic Cancer.
- Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal Cell carcinoma: a southwest oncology g...
- Prevention of mammary tumors with a chimeric HER-2 B-Cell epitope peptide vaccine.
- B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity.
- Modulation of CD4 cell cytokine production by colon Cancer-associated mucin.
- Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
- Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal Cancer.
- Human chorionic gonadotropin as a target for Cancer vaccines.
- Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: effects on chemokine production.
- Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid Tumors: a southwest oncology group study.
- Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advan...
- HIV type 1-reactive chemokine-producing CD8+ and CD4+ Cells expanded from infected lymph nodes.
- Adoptive immunotherapy of feline leukemia virus infection using autologous lymph node lymphocytes.
- Subunit peptide Cancer vaccines targeting activating mutations of the p21 ras proto-oncogene.
- Oncogene and cytokine expression of human Colorectal tumors responding to immunotherapy.
- Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid Cancers: Southwest Oncology, Group Study 8940.
- Clinical and immunologic effects of monoclonal antibody CC49 and interleukin-2 in patients with metastatic colorectal Cancer.
- Phenotypic and functional differences between human dendritic Cells derived in vitro from hematopoietic progenitors and from monocytes/macrophages.
- Antitumor and accessory immune activities of peripheral blood stem Cells mobilized with granulocyte-macrophage colony-stimulating factor.
- Isotretinoin and recombinant interferon alfa-2a therapy of metastatic Malignant melanoma.
- Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
- A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group.
- Aci-reductones enhance interleukin-2-induced lymphocyte cytotoxicity.
- Phase Ib trial of a synthetic beta human chorionic gonadotropin vaccine in patients with metastatic Cancer.
- Identification and activation of tumor-reactive Cells for adoptive immunotherapy.
- Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody.
- Application of chemical immunomodulators to the treatment of Cancer and AIDS.
- Biologic effects of the adoptive transfer of Cells depleted of monocytes with L-phenylalanine methyl ester.
- Autologous bone marrow and peripheral blood progenitor transplant for breast Cancer.
- Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.
- Adoptive immunotherapy using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
- Expansion of mucin-reactive T-helper lymphocytes from patients with colorectal Cancer.
- Synthetic hormone/growth factor subunit vaccine with application to antifertility and Cancer.
- Gastrointestinal involvement and multiple Lymphomatous polyposis in mantle-zone Lymphoma.
- Optimum management of nausea and vomiting in Cancer chemotherapy.
- Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal Cancer.
- Supportive care of the patient with Cancer.
- Induction of 2',5'-oligoadenylate synthetase activity in peripheral blood mononuclear Cells by gamma interferon.
- Contributions of benzodiazepines to Cancer therapy.
- Coexistence of porphyria cutanea tarda and autoimmune hemolytic Anemia.
- The role of IFN-beta in Cancer therapy.
- Combined effects of interferon and steroid hormones on 2'',5''-oligoadenylate synthetase activity in chronic lymphocytic leukemia Cells.
- 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic Carcinoma of the head and neck.
- Phase II trial of interferon-beta-serine in metastatic renal Cell carcinoma.
- Effects of 2'-deoxycoformycin on HL-60 Cell differentiation, adenosine deaminase, and oligoadenylate synthetase.
- Combined effects of interferon and 2'-deoxycoformycin on 2',5'-oligoadenylate synthetase and adenosine deaminase in hairy Cell and chronic lymphocytic leukemia Cells.
- Immunological effects of flavone acetic acid.
- Phase I studies of recombinant interferon-gamma.
- Human monocytes inhibit lymphokine-activated killer Cell expansion in vitro.
- Interleukin-2 therapy enhances salicylate oxidation by blood granulocytes.
- Treatment strategies for AIDS-related malignancies.
- Central Nervous system toxicity of biological response modifiers.
- Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-Cell carcinoma of the head and neck: a ...
- Modulation of hematologic and immunologic effects of high dose chemotherapy by interleukin-2 in a murine tumor model.
- Modulation of leukemic Cell sensitivity to lymphokine-activated killer cytolysis: role of interCellular adhesion molecule-1.
- Modulation of adhesion molecules on human large granular lymphocytes by interleukin-2 in vivo and in vitro.
- Bisphosphonates inhibit the growth of mesothelioma Cells in vitro and in vivo.
- Enhanced transduction of mouse bone marrow-derived dendritic Cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimula...
- Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic Cells.
- Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal Cell carcinoma patients with COX-2 tumor immunostaining.
- Noncytotoxic differentiation treatment of renal cell Cancer.
Schools
Ohio State University College Of Medicine and Public Health
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Options PPO
- CareSource
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Wellpath Preferred PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Medicare Advantage PFFS
- HealthSmart
- Choice Care PPO
- Kaiser Permanente
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medical Mutual of Ohio POS
- Medicare MCR
- MultiPlan PPO
- Mutual of Omaha
- NGS CoreSource
- Paramount
- Principal Life
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- UPMC Health Plan
- WellCare
- Wells Fargo Insurance
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
Duke University Hospital -
The Ohio State University College of Medicine
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1134177959 | |
| NPPES Provider LastName | TRIOZZI | |
| NPPES Provider FirstName | PIERRE | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 29.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134177959 |
| Last Name Of The Provider | TRIOZZI |
| First Name Of The Provider | PIERRE |
| View All |
Similar Doctors
|
|
Dr. Alan E. Lichtin, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Alberto J. Montero, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy O'Brien, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brad L. Pohlman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Stanton L. Gerson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven W. Andresen, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alok A. Khorana, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna R. Balog, MD |
|
Dr. Erica L. Campagnaro, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lalitha V. Nayak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald M. Bukowski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christos Kyriakopoulos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shaveta Vinayak, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. James P. Stevenson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy L. Silverstein, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nathan A. Berger, MD |